文献速递冠心病

直接PCI后常规延长抗凝未减少30天缺血事件:RIGHT随机双盲试验

Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction: A Multicenter, Randomized, Double-Blind Trial.
PubMed 文献 · Circulation · 2024-02-26

RIGHT试验在中国53个中心纳入2989例接受直接PCI的STEMI患者,随机接受低剂量术后抗凝或安慰剂至少48小时。结果显示两组30天主要疗效终点发生率均为2.5%(HR 1.00,95%CI 0.63~1.57),BARC 3~5级出血无差异(0.5% vs 0.7%)。常规术后抗凝安全但未减少30天缺血事件。

要点

  • 常规术后抗凝未降低30天全因死亡、非致死性心梗、非致死性卒中、支架血栓或紧急血运重建的复合终点。
  • 术后抗凝未增加BARC 3~5级出血风险,安全性可接受。
  • 各中心可选依诺肝素、普通肝素或比伐卢定方案,但试验未显示常规抗凝获益。

核心结论

  • 直接PCI后常规低剂量术后抗凝安全,但未减少30天缺血事件。

研究设计与样本

  • 研究者发起的多中心、随机、双盲、安慰剂对照、优效性试验,在中国53个中心开展。
  • 2019年1月10日至2021年9月18日共随机2989例接受直接PCI的STEMI患者。
  • 患者按中心随机接受低剂量术后抗凝或匹配安慰剂至少48小时;各中心预先选择三种抗凝方案之一:依诺肝素40 mg每日一次皮下注射、普通肝素10 U·kg·h静脉输注调整ACT至150~220秒、或比伐卢定0.2 mg·kg·h静脉输注。

主要发现

  • 主要疗效终点(30天内全因死亡、非致死性心梗、非致死性卒中、明确支架血栓或任何血管紧急血运重建)在术后抗凝组与安慰剂组均为37例(2.5%),HR 1.00(95%CI 0.63~1.57)。
  • BARC 3~5级出血在术后抗凝组8例(0.5%)、安慰剂组11例(0.7%),HR 0.74(95%CI 0.30~1.83)。

临床怎么用

  • 不推荐STEMI患者直接PCI后常规给予延长抗凝以预防缺血事件。
  • 术后抗凝未增加严重出血,但需结合个体缺血与出血风险权衡。

局限性

  • 各中心非随机选择三种抗凝方案之一,特定方案疗效仅作关键次要目的评估。
  • 随访时间为30天,未评估长期结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postprocedural anticoagulation (PPA) is frequently administered after primary percutaneous coronary intervention in ST-segment-elevation myocardial infarction, although no conclusive data support this practice. METHODS: The RIGHT trial (Comparison of Anticoagulation Prolongation vs no Anticoagulation in STEMI Patients After Primary PCI) was an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled, superiority trial conducted at 53 centers in China. Patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention were randomly assigned by center to receive low-dose PPA or matching placebo for at least 48 hours. Before trial initiation, each center selected 1 of 3 PPA regimens (40 mg of enoxaparin once daily subcutaneously; 10 U·kg·h of unfractionated heparin intravenously, adjusted to maintain activated clotting time between 150 and 220 seconds; or 0.2 mg·kg·h of bivalirudin intravenously). The primary efficacy objective was to demonstrate superiority of PPA to reduce the primary efficacy end point of all-cause death, nonfatal myocardial infarction, nonfatal stroke, stent thrombosis (definite), or urgent revascularization (any vessel) within 30 days. The key secondary objective was to evaluate the effect of each specific anticoagulation regimen (enoxaparin, unfractionated heparin, or bivalirudin) on the primary efficacy end point. The primary safety end point was Bleeding Academic Research Consortium 3 to 5 bleeding at 30 days. RESULTS: Between January 10, 2019, and September 18, 2021, a total of 2989 patients were randomized. The primary efficacy end point occurred in 37 patients (2.5%) in both the PPA and placebo groups (hazard ratio, 1.00 [95% CI, 0.63 to 1.57]). The incidence of Bleeding Academic Research Consortium 3 to 5 bleeding did not differ between the PPA and placebo groups (8 [0.5%] vs 11 [0.7%] patients; hazard ratio, 0.74 [95% CI, 0.30 to 1.83]). CONCLUSIONS: Routine PPA after primary percutaneous coronary intervention was safe but did not reduce 30-day ischemic events. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03664180.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Yan, Guo, Wang, et al. Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction: A Multicenter, Randomized, Double-Blind Trial. Circulation. 2024. PMID: 38406848. doi:10.1161/CIRCULATIONAHA.123.067079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。